These TAAs are captured by antigen-presenting cells (APCs) and then presented to CD8+ T cells, resulting in substantial increases in the number and diversity of TAAs that can stimulate robust tumour-specific immune responses in which specific CD8+ T cells recognize and attack both the primary tumour and metastatic disease [7, 9]. This evidence concerns the gene CD8A and neoplasm.